learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Search
forLearn
5 / 801 resultslearn Beta glucan
learn multipeptides
learn oligopeptide-71
learn sh-Polypeptide-7
Research
5 / 613 resultsresearch Nonscarring alopecia in systemic lupus erythematosus: A cross-sectional study with trichoscopic, histopathologic, and immunopathologic analyses
Hair loss in lupus patients indicates higher disease activity.
research Symmetrical acrokeratoderma: A peculiar entity in China? Clinicopathologic and immunopathologic study of 34 new cases
Symmetrical Acrokeratoderma (SAK) may be a unique skin condition in China, lacking specific treatment and needing long-term monitoring.
research Frontal Fibrosing Alopecia and the Role of Cosmeceuticals in Its Pathogenesis
Cosmeceuticals like sunscreens may trigger frontal fibrosing alopecia, but more research is needed.
research Single-center analysis of patients with frontal fibrosing alopecia: evidence for hypothyroidism and a good quality of life
Frontal fibrosing alopecia is linked to hypothyroidism but doesn't affect quality of life.
research IMMUNOPATHOLOGY OF THE HUMAN HAIR FOLLICLE
The document concludes that immune system abnormalities cause alopecia areata, but the exact process is still not completely understood.
Community Join
5 / 1000+ resultscommunity A meta analysis of 18 popular hair loss treatments. An 2022 guide on efficacy. From finasteride and minoxidil to caffeine shampoo, saw palmetto and biotin. 96 Scientific References included.
Most hair loss treatments are ineffective; only finasteride, dutasteride, and minoxidil show effectiveness.
community Seeking Analysis: Receded Temple Closeups for Scarring or AGA Signs
The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community [Part 2] – Sharing data for collaborative analytics on pyrilutamide
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.